Clinical Pharmacokinetics

, Volume 23, Issue 1, pp 42–61 | Cite as

Pharmacokinetics and Therapeutic Efficacy of Retinoids in Skin Diseases

  • Frederik Grønhøj Larsen
  • Folmer Nielsen-Kudsk
  • Preben Jakobsen
  • Kaare Weismann
  • Knud Kragballe
Review Article Pharmacokinetics — Therapeutics

Summary

The retinoids are a class of compounds that includes the natural forms and synthetic analogues of vitamin A. Isotretinoin, often referred to as a first generation retinoid, may be of considerable benefit to patients with severe, recalcitrant acne. Etretinate and acitretin, 2 aromatic compounds representing the second generation, have found their major success in the treatment of psoriasis, particularly in combination with more traditional therapies. Retinoid therapy is associated with a distinctive adverse effect profile typical of hypervitaminosis A; thus, it is especially important that fertile women undergoing retinoid therapy adhere to a contraceptive regimen. These drugs are extensively metabolised and only traces of unchanged drugs are eliminated in urine. The terminal elimination half-lives of isotretinoin, etretinate and acitretin after long term treatment are up to 20h, 120 days and 48h, respectively. Because of lack of definite correlation between plasma concentration and desired pharmacological effects, in conjunction with the very pronounced inter- and intraindividual variation in systemic availability (15 to 90%) after oral administration of these drugs, initial dosages in individual patients can only be roughly judged on the basis of the general pharmacokinetics of the agents. Later dosage adjustments should be made on the basis of monitoring of both plasma drug (and possible metabolite) concentrations, and the efficacy and tolerability of the drugs.

Keywords

Psoriasis Acne Retinoid Isotretinoin Tretinoin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Berbis P, Bun H, Al Mallah NR, Durand A, Rognin C, et al. Residual plasma concentrations of acitretin (Ro 10-1670) and its metabolite (Ro 13-7652) after chronic administration. Dermatologica 177: 244–246, 1988aPubMedCrossRefGoogle Scholar
  2. Berbis P, Bun H, Geiger JM, Rognin C, Durand A, et al. Acitretin (Ro 10-1670) and oral contraceptives: interaction study. Archives of Dermatological Research 280: 388–389, 1988bPubMedCrossRefGoogle Scholar
  3. Berbis P, Geiger J-M, Vaisse C, Rognin C, Privat Y. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 178: 88–92, 1989PubMedCrossRefGoogle Scholar
  4. Bollag W. Therapeutic effects of an aromatic retinoic acid analog on chemically induced skin papillomas and carcinoma of mice. European Journal of Cancer 10: 731–737, 1974PubMedCrossRefGoogle Scholar
  5. Bollag W. The development of retinoids in experimental and clinical oncology and dermatology. Journal of the American Academy of Dermatology 9: 797–805, 1983PubMedCrossRefGoogle Scholar
  6. Bollag W, Geiger J-M. The development of retinoids in dermatology. In Cunliffe & Miller (Eds) Retinoid therapy: a review of clinical and laboratory research. Proceedings of an international conference (London), pp. 1–7, MTP Press Limited, 1984Google Scholar
  7. Bouclier M, Shroot B, Eustache J, Hensby CN. A rapid and simple test system for the evaluation of the inhibitory activity in the hairless rat epidermis. Journal of Pharmacological Methods 16: 151–160, 1986PubMedCrossRefGoogle Scholar
  8. Brazzell RK, Colburn WA. Pharmacokinetics of the retinoids isotretinoin and etretinate: a comparative review. Journal of the American Academy of Dermatology 6: 642–651, 1982CrossRefGoogle Scholar
  9. Brazzell RK, Vane FM, Ehmann CW, Colburn WA. Pharmacokinetics of isotretinoin during repetitive dosing to patients. European Journal of Clinical Pharmacology 24: 695–702, 1983PubMedCrossRefGoogle Scholar
  10. Brindley CJ. Overview of recent clinical pharmacokinetic studies with acitretin (Ro 10-1670, Etretin). Dermatologica 178: 79–87, 1989PubMedCrossRefGoogle Scholar
  11. Brion DE, Raynaud F, Plet A, Laurent P, Leduc B. Effect of retinoids on cAMP-mediated events in human psoriatic fibroblasts. In Saurat (Ed.) Retinoids: new trends in research and therapy. Retinoid Symposium, Geneva, pp. 189–193, Karger, Basel, 1985Google Scholar
  12. Camisa C, Eisenstat B, Ragaz A, Weissmann G. The effect of retinoids on neutrophil functions in vitro. Journal of the American Academy of Dermatology 6: 620–629, 1982PubMedCrossRefGoogle Scholar
  13. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. Journal of Clinical Pharmacology 23: 534–539, 1983bPubMedGoogle Scholar
  14. Colburn WA, Vane FM, Shorter HJ. Pharmacokinetics of isotretinoin and its major blood metabolite following a single oral dose to man. European Journal of Clinical Pharmacology 24: 689–694, 1983aPubMedCrossRefGoogle Scholar
  15. Cotter S, Bugge CJL, Colburn WA. Role of gut contents, intestinal wall, and liver on the first pass metabolism and absolute bioavailability of isotretinoin in the dog. Drug Metabolism and Disposition 2: 458–462, 1983Google Scholar
  16. Cunliffe WJ, Norris JFB. Isotretinoin: an explanation for its long-term benefit. Dermatologica 175 (Suppl. 1): 133–137, 1987PubMedCrossRefGoogle Scholar
  17. DiGiovanna JJ, Gross EG, McClean SW, Ruddel ME, Gantt G, et al. Etretinate: effect of milk intake on absorption. Journal of Investigative Dermatology 82: 636–640, 1984PubMedCrossRefGoogle Scholar
  18. DiGiovanna JJ, Helfgott RK, Gerber LH, Peck GL. Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. New England Journal of Medicine 315: 1177–1182, 1986PubMedCrossRefGoogle Scholar
  19. DiGiovanna JJ, Zech LA, Ruddel ME, Gantt G, Peck GL. Etretinate: persistent serum levels after long-term therapy. Archives of Dermatology 125: 246–251, 1989PubMedCrossRefGoogle Scholar
  20. Dubertret L, Lebreton C, Touraine R. Inhibition of neutrophil migration by etretinate and its main metabolite. British Journal of Dermatology 107: 681–685, 1982PubMedCrossRefGoogle Scholar
  21. Dubertret L, Touraine R. The role of neutrophil leukocytes in the psoriatic epidermal process: preliminary results. In Farber & Cox (Eds) Psoriasis: proceedings of the second international symposium, pp. 371–374, Yorke Medical Books, New York, 1976Google Scholar
  22. Ellis CN, Voorhees JJ. Etretinate therapy. Journal of the American Academy of Dermatology 16: 267–291, 1987PubMedCrossRefGoogle Scholar
  23. Farrell L, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoic acid. Journal of the American Academy of Dermatology 3: 602–611, 1980PubMedCrossRefGoogle Scholar
  24. Fraunfelder FT, LaBraico JM, Meyer SM. Adverse ocular reactions possibly associated with isotretinoin. American Journal of Ophthalmology 100: 534–537, 1985PubMedGoogle Scholar
  25. Giguere V, Ong ES, Segui P, Evans RM. Identification of a receptor for the morphogen retinoic acid. Nature 330: 624–629, 1987PubMedCrossRefGoogle Scholar
  26. Goldfarb MT, Ellis CN, Voorhees JJ. Short-term and long-term considerations in the management of psoriasis with retinoids. Dermatologica 175 (Suppl. 1): 100–106, 1987PubMedCrossRefGoogle Scholar
  27. Goldstein JA, Comite H, Mescon H, Pochi PE. Isotretinoin in the treatment of acne: histologic changes, sebum production and clinical observations. Archives of Dermatology 118: 555–558, 1982aPubMedCrossRefGoogle Scholar
  28. Goldstein JA, Socha-Szott A, Thomsen RJ, Pochi PE, Shalita AR, et al. Comparative effect of isotretinoin and etretinate on acne and sebaceous gland secretion. Journal of the American Academy of Dermatology 6: 760–765, 1982bPubMedCrossRefGoogle Scholar
  29. Gollnick H, Bauer R, Brindley C, Orfanos CE, Plewig G, et al. Acitretin versus etretinate in psoriasis. Journal of the American Academy of Dermatology 19: 458–469, 1988PubMedCrossRefGoogle Scholar
  30. Goodman GE, Einspahr JG, Alberts DS, Davis TP, Leigh SA, et al. Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. Cancer Research 42: 2087–2091, 1982PubMedGoogle Scholar
  31. Grekin RC, Ellis CN, Goldstein NG, Swanson NA, Anderson TF, et al. Decreased urinary polyamines in patients with psoriasis treated with etretinate. Journal of Investigative Dermatology 80: 181–184, 1983PubMedCrossRefGoogle Scholar
  32. Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ. Side-effect profile of acitretin therapy in psoriasis. Journal of the American Academy of Dermatology 20: 1088–1093, 1989PubMedCrossRefGoogle Scholar
  33. Hanni R. Pharmacokinetic and metabolic pathways of systemically applied retinoids. Dermatologica 157 (Suppl. 1): 5–10, 1978PubMedCrossRefGoogle Scholar
  34. Happle R, Traupe H, Bounameaux Y, Fisch T. Teratogene Wirkung von Etretinat beim Menschen. Deutsche Medizinische Wochenschrift 109: 1476–1480, 1984PubMedCrossRefGoogle Scholar
  35. Harms M. Systemic isotretinoin (‘Roaccutan’): a unique therapeutic effect and its implications in the pathogenesis of acne. Editions Roche, Basel, 1989Google Scholar
  36. Harms M, Masouye I, Radeff B. The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study. Dermatologica 172: 148–153, 1986PubMedCrossRefGoogle Scholar
  37. Holian O, Kumar R. Cyclic AMP and cyclic AMP-dependent protein kinase in mouse skin II: in vitro effects of isotretinoin and etretinate. Archives of Dermatological Research 278: 161–164, 1985PubMedCrossRefGoogle Scholar
  38. Keddie F. Use of vitamin A in the treatment of cutaneous diseases: relation to estrogen and vitamin B complex. Archives of Dermatology and Syphilology 58: 64–73, 1948PubMedCrossRefGoogle Scholar
  39. Kemper C, Holland ML, Thorne EG, Anders J, Wills RJ. Percutaneous absorption of 3H-tretinoin following long-term administration of topical tretinoin. Abstract. Dermatologica 181: 351, 1990Google Scholar
  40. Khoo KC, Reik D, Colburn WA. Pharmacokinetics of isotretinoin following a single oral dose. Journal of Clinical Pharmacology 22: 395–402, 1982PubMedCrossRefGoogle Scholar
  41. Kilcoyne RF. Effects of retinoids in bone. Journal of the American Academy of Dermatology 19: 212–216, 1988PubMedCrossRefGoogle Scholar
  42. King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. British Journal of Dermatology 107: 583–590, 1982PubMedCrossRefGoogle Scholar
  43. Kingston TP, Matt LH, Lowe NJ. Etretin therapy for severe psoriasis. Archives of Dermatology 123: 55–58, 1987PubMedCrossRefGoogle Scholar
  44. Kochhar DM, Penner JD, Minutella LM. Biotransformation of etretinate and developmental toxicity of etretin and other aromatic retinoids in teratogenesis bioassays. Drug Metabolism and Disposition 17: 618–624, 1989PubMedGoogle Scholar
  45. Korner WF, Vollum J. New aspects of the tolerance of retinol in humans. International Journal of Vitamins and Nutritional Research 45: 363–372, 1975Google Scholar
  46. Kragballe K, Jansen CT, Geiger J-M, Bjerke JR, Falk ES, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Acta Dermato-Venereologica 69: 35–40, 1989PubMedGoogle Scholar
  47. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, et al. Retinoic acid embryopathy. New England Journal of Medicine 313: 837–841, 1985PubMedCrossRefGoogle Scholar
  48. Landthaler M, Kummermehr J, Wagner A, Plewig G. Inhibitory effects of 13-cis-retinoic acid on human sebaceous glands. Archives of Dermatological Research 269: 297–309, 1980PubMedCrossRefGoogle Scholar
  49. Larsen FG, Jakobsen P, Eriksen H, Grønhøj J, Kragballe K, et al. The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. Journal of Clinical Pharmacology 31: 477–483, 1991PubMedGoogle Scholar
  50. Larsen FG, Jakobsen P, Larsen CG, Kragballe K, Nielsen-Kudsk F. Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. Pharmacology and Toxicology 62: 159–165, 1988PubMedCrossRefGoogle Scholar
  51. Larsen FG, Jakobsen P, Larsen CG, Nørgaard A, Kragballe K, et al. Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. Pharmacology and Toxicology 61: 85–88, 1987PubMedCrossRefGoogle Scholar
  52. Larsen FG, Nielsen-Kudsk F, Jakobsen P, Kragballe K. Pharmacokinetics of etretinate in psoriatic patients with liver fibrosis. Pharmacology and Toxicology 65: 393–397, 1989PubMedCrossRefGoogle Scholar
  53. Larsen FG, Nielsen-Kudsk F, Jakobsen P, Schrøder H, Kragballe K. Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. Journal of Clinical Pharmacology 30: 802–807, 1990PubMedGoogle Scholar
  54. Lebowitz MA, Berson DS. Ocular effects of oral retinoids. Journal of the American Academy of Dermatology 19: 209–211, 1988PubMedCrossRefGoogle Scholar
  55. Leyden JJ, McGinley KJ, Foglia AN. Qualitative and quantitative changes in cutaneous bacteria associated with systemic isotretinoin therapy for acne conglobata. Journal of Investigative Dermatology 86: 390–393, 1986PubMedCrossRefGoogle Scholar
  56. Lowe NJ, Kaplan R, Breeding J. Etretinate treatment for psoriasis inhibits epidermal ornithine decarboxylase. Journal of the American Academy of Dermatology 6: 697–698, 1982PubMedCrossRefGoogle Scholar
  57. Marsden JR. Lipid metabolism and retinoid therapy. Pharmacology and Therapeutics 40: 55–65, 1989PubMedCrossRefGoogle Scholar
  58. Massarella J, Vane F, Bugge C, Rodriguez L, Cunningham WJ, et al. Etretinate kinetics during chronic dosing in severe psoriasis. Clinical Pharmacology and Therapeutics 37: 439–446, 1985PubMedCrossRefGoogle Scholar
  59. Matt L, Lazarus N, Lowe NJ. Newer retinoids for psoriasis: early clinical studies. Pharmacology and Therapeutics 40: 157–169, 1989PubMedCrossRefGoogle Scholar
  60. McNamara PJ, Jewell RC, Jensen BK, Brindley CJ. Food increases the bioavailability of acitretin. Journal of Clinical Pharmacology 28: 1051–1055, 1988PubMedGoogle Scholar
  61. Meigel W, Gollnick H, Wokalek H, Plewig G. Orale Behandlung der Acne conglobata mit 13-cis-Retinsaure. Der Hautarzt 34: 387–397, 1983Google Scholar
  62. Norris DA, Osborn R, Robinson W, Tonnesen MG. Isotretinoin produces significant inhibition of monocyte and neutrophil chemotaxis in vivo in patients with cystic acne. Journal of Investigative Dermatology 89: 38–43, 1987PubMedCrossRefGoogle Scholar
  63. Orfanos CE, Ehlert R, Gollnick H. The retinoids: a review of their clinical pharmacology and therapeutic use. Drugs 34: 459–503, 1987PubMedCrossRefGoogle Scholar
  64. Orfanos CE, Mahrle G, Goerz G, Happle R, Hofbauer M, et al. Laboratory investigations in patients with generalized psoriasis under oral retinoid treatment. Dermatologica 159: 62–70, 1979PubMedCrossRefGoogle Scholar
  65. Paravicini U. Pharmacokinetics and metabolism of oral aromatic retinoids. In Orfanos et al. (Eds) Retinoids: advances in basic research and therapy, pp. 13–20, Springer-Verlag, Berlin, 1981Google Scholar
  66. Paravicini U, Camenzind M, Gower M, Geiger JM, Saurat JH. Multiple dose pharmacokinetics of Ro 10-1670, the main metabolite of etretinate (Tigason). In Saurat (Ed.) Retinoids: new trends in research and therapy, pp. 289–292, Karger, Basel, 1985Google Scholar
  67. Paravicini U, Stockel K, MacNamara PJ, Hanni R, Busslinger A. On metabolism and pharmacokinetics of an aromatic retinoid. Annals of the New York Academy of Sciences 359: 54–67, 1981PubMedCrossRefGoogle Scholar
  68. Peck GL. Retinoids: therapeutic use in dermatology. Drugs 24: 341–351, 1982PubMedCrossRefGoogle Scholar
  69. Peck GL, Olsen TG, Butkus D, Pandya M, Arnaud-Battandier J, et al. Isotretinoin versus placebo in the treatment of cystic acne. Journal of the American Academy of Dermatology 6: 735–745, 1982PubMedCrossRefGoogle Scholar
  70. Peck GL, Olsen TG, Yoder FW. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. New England Journal of Medicine 300: 329–333, 1979PubMedCrossRefGoogle Scholar
  71. Petkovich M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330: 444–450, 1987PubMedCrossRefGoogle Scholar
  72. Pittsley RA, Yoder FW. Retinoid hyperostosis: skeletal toxicity associated with long-term administration of 13-cis-retinoic acid for refractory ichthyosis. New England Journal of Medicine 308: 1012–1014, 1983PubMedCrossRefGoogle Scholar
  73. Rasmussen H, Goodman D. Relationship between calcium and cyclic nucleotides in cell activation. Physiological Reviews 57: 421–509, 1977PubMedGoogle Scholar
  74. Ray S, Begg E, Wade D. Pharmacokinetics of an aromatic retinoid, RO 10-9359, and its metabolites RO 10-1670 and RO 13-7652 in patients with Darier’s disease. Clinical and Experimental Pharmacology and Physiology 8: 674, 1981Google Scholar
  75. Raynaud F, Leduc C, Anderson WB, Evain-Brion D. Retinoid treatment of human psoriatic fibroblasts induces an increase in cyclic AMP-dependent protein kinase activity. Journal of Investigative Dermatology 89: 105–110, 1987PubMedCrossRefGoogle Scholar
  76. Roenigk HH, Gibstine C, Glazer S, Sparberg M, Yokoo H. Serial liver biopsies in psoriatic patients receiving long-term etretinate. British Journal of Dermatology 112: 77–81, 1985PubMedCrossRefGoogle Scholar
  77. Rollman O, Pihl-Lundin I. Acitretin excretion into human breast milk. Acta Dermato-Venereologica 70: 487–490, 1990PubMedGoogle Scholar
  78. Rollman O, Vahlquist A. Retinoid concentrations in skin, serum and adipose tissue of patients treated with etretinate. British Journal of Dermatology 109: 439–447, 1983PubMedCrossRefGoogle Scholar
  79. Rollman O, Vahlquist A. Oral isotretinoin (13-cis-retinoic acid) therapy in severe acne: drug and vitamin A concentrations in serum and skin. Journal of Investigative Dermatology 86: 384–389, 1986PubMedCrossRefGoogle Scholar
  80. Saurat J-H, Hirschel-Scholz S, Salomon D, Siegenthaler G. Human skin retinoid-binding proteins and therapy with synthetic retinoids: a still unexplained link. Dermatologica 175 (Suppl. 1): 13–19, 1987PubMedCrossRefGoogle Scholar
  81. Shalita AR. Mucocutaneous and systemic toxicity of retinoids: monitoring and management. Dermatologica 175 (Suppl. 1): 151–157, 1987PubMedCrossRefGoogle Scholar
  82. Shalita AR. Lipid and teratogenic effects of retinoids. Journal of the American Academy of Dermatology 19: 197–198, 1988PubMedCrossRefGoogle Scholar
  83. Shalita AR, Armstrong RB, Leyden JJ, Pochi PE, Strauss JS. Isotretinoin revisited. Cutis 42: 1–19, 1988PubMedGoogle Scholar
  84. Siegenthaler G, Saurat J-H. Retinoid binding proteins and human skin. Pharmacology and Therapeutics 40: 45–54, 1989PubMedCrossRefGoogle Scholar
  85. Sporn MB, Roberts AB. What is a retinoid? In Retinoids, differentiation and disease. Ciba Foundation Symposium, No. 113, pp. 1–5, Pitman, London, 1985Google Scholar
  86. Stewart ME, Benoit AM, Stranieri AM, Rapini RP, Strauss JS, et al. Effect of oral 13-cis-retinoic acid at three dose levels on sustainable rates of sebum secretion and on acne. Journal of the American Academy of Dermatology 8: 532–538, 1983PubMedCrossRefGoogle Scholar
  87. Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, et al. Isotretinoin therapy of acne: results of a multicenter dose-response study. Journal of the American Academy of Dermatology 10: 490–496, 1984PubMedCrossRefGoogle Scholar
  88. Strauss JS, Stranieri AM. Changes in long-term sebum production from isotretinoin therapy. Journal of the American Academy of Dermatology 6: 751–755, 1982PubMedCrossRefGoogle Scholar
  89. Stuck AE, Brindley CJ, Busslinger A, Frey FJ. Pharmacokinetics of acitretin and its 13-cis metabolite in patients on haemodialysis. British Journal of Clinical Pharmacology 27: 301–304, 1989PubMedCrossRefGoogle Scholar
  90. Taieb A, Maleville J. Retinoid dermatitis mimicking ‘eczema craquele’. Acta Dermato-Venereologica 65: 570, 1985PubMedGoogle Scholar
  91. Tfelt-Hansen P, Knudsen B, Petersen E, Sørensen EB. Spinal cord compression after long-term etretinate. Lancet 2: 325–326, 1989PubMedCrossRefGoogle Scholar
  92. Tsambaos D, Orfanos CE. Effects of oral retinoid on dermal components in human and animal skin. In Orfanos et al. (Eds) Retinoids: advances in basic research and therapy, pp. 99–108, Springer-Verlag, Berlin, 1981Google Scholar
  93. Vahlquist A. Etretinate pharmacokinetics in chronic renal failure. Dermatologica 175: 224–228, 1987PubMedCrossRefGoogle Scholar
  94. Vahlquist A, Michaelsson G, Kober A, Sjoholm I, Palmskog G, et al. In Orfanos et al. (Eds) Retinoids: advances in basic research and therapy, pp 109–116, Springer-Verlag, Berlin, 1981Google Scholar
  95. Vahlquist C, Michaelsson G, Vahlquist A, Vessby B. A sequential comparison of etretinate (Tigason) and isotretinoin (Roaccutane) with special regard to their effects on serum lipoproteins. British Journal of Dermatology 112: 69–76, 1985PubMedCrossRefGoogle Scholar
  96. Vahlquist C, Selinus I, Vessby B. Serum lipid changes during acitretin (etretin) treatment of psoriasis and palmoplantar pustulosis. Acta Dermato-Venereologica 68: 300–305, 1988PubMedGoogle Scholar
  97. van Ditzhuijsen TJ, van Haelst UJ, van Dooren Greebe, van de Kerkhof PC, Yap SH. Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin). Journal of Hepatology 11: 185–188, 1990PubMedCrossRefGoogle Scholar
  98. Weiss VC, Layden T, Spinowitz A, Buys M, Nemchausky BA, et al. Chronic active hepatitis associated with etretinate therapy. British Journal of Dermatology 112: 591–597, 1985PubMedCrossRefGoogle Scholar
  99. Wolska H, Jablonska S, Bounameaux Y. Etretinate in severe psoriasis. Journal of the American Academy of Dermatology 9: 883–889, 1983PubMedCrossRefGoogle Scholar
  100. Zachariae H, Foged E, Bjerring P, Kragballe K, Søgaard H. Liver biopsy during etretinate (Tigason) treatment. In Saurat (Ed.) Retinoids: new trends in research and therapy, pp. 494–497, Karger, Basel, 1985Google Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • Frederik Grønhøj Larsen
    • 1
    • 2
    • 3
  • Folmer Nielsen-Kudsk
    • 1
    • 2
    • 3
  • Preben Jakobsen
    • 1
    • 2
    • 3
  • Kaare Weismann
    • 1
    • 2
    • 3
  • Knud Kragballe
    • 1
    • 2
    • 3
  1. 1.Department of DermatologyBispebjerg HospitalCopenhagen NVDenmark
  2. 2.Institute of PharmacologyUniversity of AarhusDenmark
  3. 3.Department of DermatologyMarselisborg HospitalAarhusDenmark

Personalised recommendations